Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018
pdf

Keywords

Incidence, Mortality, Ovarian cancer, Human Development Index, World

Abstract

Ovarian cancer is the seventh most common cancer among women, accounting for about 4% of all cancers associated with women. This is a descriptive cross-sectional study based on extraction of cancer incidence data and cancer mortality rates from the Global Cancer Data in 2018. The incidence and mortality rates and ovarian cancer distribution maps were drawn for World countries. To analyze data, correlation test and regression tests were used to evaluate the correlation between its incidence and mortality with HDI. The results showed that there was a positive and significant correlation between ovarian cancer incidence (R = 0.409, P <0.0001) and mortality (R = 0.193, P <0.05) with HDI. The results showed that there was a positive and significant correlation between incidence with GNI ,MYS ,LEB and EYS ( P <0.0001). The results also demonstrated that there was a positive and significant correlation between mortality and GNI, MYS, LEB and EYS ( P <0.05).The linear regression model showed that a higher MYS [B = 0.2, CI95%: (- 0.03,0.5)] significantly increased the incidence of ovarian cancer and increased MYS [B = 0.2, CI95% (0.03, 0.4)] increased mortality. Given the positive and significant correlation between ovarian cancer incidence and mortality with HDI, attention to risk factors in these countries can be effective in curbing its incidence and mortality.

https://doi.org/10.15167/2421-4248/jpmh2021.62.1.1606
pdf

References

1. Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. International journal of cancer 2016;139:2436-46.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394-424.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015;136:E359-E86.
4. Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M, Salehiniya H. The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. ecancermedicalscience 2016;10.
5. Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev 2014;15:7665-71.
6. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta obstetricia et gynecologica Scandinavica 2004;83:783-95.
7. Tsilidis K, Allen N, Key T, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British journal of cancer 2011;105:1436.
8. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007. Т 2007;1:52.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 2010;127:2893-917.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians 2011;61:69-90.
11. Murray CJ, Lopez AD, Organization WH. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary. 1996.
12. Rahmani K, Moradi-Lakeh M, Mansori K, Bidokhti F, Asadi-Lari M. Global Inequalities in Incidence and Mortality of Ovarian Cancer and Associated Factors: An Ecological Study. Alzheimers Parkinsonism Res Ther 2018;1:1001.
13. Mao Y, Desmeules M, Semenciw R, Hill G, Gaudette L, Wigle D. Increasing brain cancer rates in Canada. CMAJ: Canadian Medical Association Journal 1991;145:1583.
14. Greiman AK, Rosoff JS, Prasad SM. Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality. BJU international 2017;120:799-807.
15. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. The lancet oncology 2012;13:790-801.
16. Goodarzi E, Moslem A, Feizhadad H, Jarrahi AM, Adineh HA, Sohrabivafa M, et al. Epidemiology, incidence and mortality of thyroid cancer and their relationship with the human development index in the world: An ecology study in 2018. Advances in Human Biology 2019;9:162.
17. Keng SL, Wahab SBA, Chiu LB, Yusuf A. Awareness of ovarian cancer risk factors among women in Malaysia: a preliminary study. Asian Pac J Cancer Prev 2015;16:537-40.
18. Kiadaliri AA. Social disparity in breast and ovarian cancer incidence in iran, 2003-2009: a time trend province-level study. Journal of breast cancer 2013;16:372-7.
19. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health 2019;11:287.